News

New neurological deficits were a predictor of long-term survival regardless of the status epilepticus cause and were associated with a 5-fold increase in the odds of death at 2 years after status epilepticus diagnosis.

Over 24 months, treatment with siponimod (Mayzent; Novartis) was associated with improvements in brain tissue integrity and myelination within newly formed normalized magnetization transfer ratio lesions.

The medical director and chief medical officer of the New England Center for Neurology and Headache discussed notable data from the STEMTRA trial, and the progress made in the field of regenerative medicine. [WATCH TIME: 2 minutes]

As a primary investigator for fenfluramine’s pivotal phase 3 program, Kelly Knupp, MD, MSCS, FAES, provided insight on new results presented at AAN 2022, as well as the positive ripple effect its recent approval brings to patients with Lennox-Gastaut syndrome.

Alnylam’s investigational subcutaneous RNAi therapy is in development for both wild-type and hereditary transthyretin-mediated amyloidosis, with data from the phase 3 HELIOS-A trial demonstrating its potential in treating associated polyneuropathy.

In addition to demonstrating significant differences in slowing functional decline, those on gamma sensory stimulation also demonstrated a significant reduction in brain atrophy relative to the sham group in the OVERTURE study.

The assistant professor of neurology at the University of Pennsylvania discussed stroke risk among patients with COVID-19 and the need to seek neurological consultation. [WATCH TIME: 3 minutes]

Following their data presentation on AMX0035 at AAN 2022, Justin Klee and Josh Cohen, the co-CEOs and co-founders of Amylyx Pharmaceuticals, shared their perspectives on the agent.

A recent study showed that use of STIMVIEW XT helped adjust patient stimulation by an average of 20 minutes, lowering the programming time by 56%.

The investigational agent was well-tolerated, with no new safety signals and no indication of worsening of supine hypertension based on 24-hour monitoring.

Adverse events were balanced across treatment and placebo groups, with no observed treatment-associated elevations in cerebrospinal fluid white blood cell counts or protein.

In addition to significantly less disability observed in tenecteplase-treated patients, this group was also administered treatment 9.40 minutes faster than those on alteplase.

Shephard Mpofu, MD, the senior vice president and chief medical officer at Novartis Gene Therapies, offered his perspective on the latest phase 3 data of onasemnogene abeparvovec (Zolgensma) in SMA treatment.

EEG Talk is a series dedicated to teaching electroencephalogram (EEG) reading skills in neurology in a way that is both digestible and fun. New episodes featuring special guests in the field are posted regularly on Mondays.

Robert K. Shin, MD, offered his perspective on the novel therapies being developed for multiple sclerosis, highlighting the potential of Bruton tyrosine kinase inhibitors for progressive disease.

The mean bodyweight-normalized infant rimegepant dose was 0.0005 mg/kg/day, and the mean estimated relative infant dose was 0.51%, therefore indicating the study drug results in less than 1% relative infant dose in human milk.

The professor of neurology at NYU Langone Grossman School of Medicine broke down the knowns and unknowns about long-term changes related to COVID-19, their legitimacy, and associations with neurodegenerative disorders. [WATCH TIME: 6 minutes]

Here's what is coming soon to NeurologyLive®.

Data presented at the 2022 AAN Annual Meeting from the ALITHIOS and KYRIOS trials suggest that ofatumumab (Kesimpta; Novartis), an anti-CD20 therapy, is safe with up to 4 years of treatment and does not prevent the mounting of an immune response to mRNA vaccines.

After showing several significant differences between placebo, the company has planned a phase 3 study that will assess the therapeutic in a cohort of 230 adults with FSHD.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

Among triptan non/past use and current use patients, investigators observed refill decreases of 15.3% and 16.8%, respectively, in the 9 months following rimegepant treatment.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD. [LISTEN TIME: 32 minutes]

Neurology News Network for the week ending April 9, 2022. [WATCH TIME: 4 minutes]

Ludwig Kappos, MD, FEAN, FAAN, provided insight on a new analysis that showed greater proportions of patients achieving no evidence of disease activity on ozanimod compared with interferon ß-1a.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 8, 2022.

The pediatric neurologist and epilepsy specialist at Colorado Children’s Hospital discussed new data presented at AAN 2022 on the use of recently approved fenfluramine in patients with Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

As a result of treatment with the Vercise Genus DBS system, patients reduced their use of anti-parkinsonian medications while maintaining improvements in quality of life.

Following the switch to ubrogepant, more than half of patients with migraine had reduced use of triptans and more than one-third of patients had reduced use of anti-inflammatory drugs.

The clinical research director of the UCSF Multiple Sclerosis Center offer his perspective on the 3 available agents for the treatment of patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 2 minutes]